TabletsClinical Overview
Dapagliflozin (5 mg, 10 mg) is a pioneer selective sodium-glucose co-transporter 2 (SGLT2) inhibitor on the WHO Model List of Essential Medicines. It acts in the S1 segment of the renal proximal tubule, blocking glucose and sodium reabsorption and promoting the urinary excretion of 70 to 80 grams of glucose per day. In addition to glycemic reduction, it induces osmotic diuresis, decreases intraglomerular pressure, reduces cardiac preload and afterload, and confers landmark cardio-renal protection. Indicated for type 2 diabetes mellitus, heart failure with reduced or preserved ejection fraction (HFrEF/HFpEF), and chronic kidney disease (CKD) to slow renal decline.
Active Pharmaceutical Ingredients
Verified Clinical References
Usage Guidelines
Take orally once daily in the morning with a full glass of water, with or without food. Drink abundant water throughout the day to avoid dehydration. Maintain good genital hygiene.
General Administration Advice: Adhere strictly to the prescribed dosage, frequency, and treatment course. For oral medications, swallow with sufficient water. Never stop antibiotics, psychiatric medications, or antihypertensives abruptly without clinical direction.
Possible Side Effects
Common: Genital fungal infections (vulvovaginal candidiasis, balanitis), urinary tract infections, increased urination, thirst, mild hypotension. Rare/Severe: Euglycemic diabetic ketoacidosis (DKA with normal or mildly elevated blood sugar), necrotizing fasciitis of the perineum (Fournier's gangrene), urosepsis, and acute volume depletion/hypotension.
*Note: Individual physiological responses vary. While many patients experience few or no side effects, notify your treating physician if adverse reactions persist or if hypersensitivity (angioedema, skin rash, dyspnea) occurs.
Precautions & Warnings
Euglycemic DKA warning: Hold medication 3 days prior to major surgery or during severe acute illness (infections, prolonged fasting). Check blood ketones immediately if unexplained nausea, vomiting, malaise, or shortness of breath develops. Contraindicated in dialysis. Practice daily perineal hygiene to prevent fungal infections.
Schedule H (Prescription Required)
This medication is scheduled under statutory drug regulatory frameworks (CDSCO / Drugs & Cosmetics Rules). Dispensing requires a valid medical prescription from a registered medical practitioner. Self-medication or unsupervised dosage adjustment carries significant clinical risks.
Medical Disclaimer: Statutory Clinical Disclaimer: The information provided is for educational and price-transparency purposes only and does not constitute medical advice, clinical diagnosis, or treatment recommendations. Always consult a registered endocrinologist, diabetologist, or qualified physician before initiating, adjusting dosages of, or substituting any antidiabetic or hormonal medication.
Dapagliflozin 10mg + Metformin Hydrochloride (Extended Release) 1000mg Tablets
Metformin Hydrochloride and Dapagliflozin unites a biguanide with an oral sodium-glucose co-transporter 2 (SGLT2) inhibitor on the WHO Model List of Essential Medicines. Metformin reduces hepatic glucose production and enhances insulin sensitivity, while dapagliflozin acts insulin-independently in the proximal renal tubules to block glucose reabsorption, promoting the urinary excretion of approximately 70-80 grams of glucose per day (equating to 280-320 kcal/day), producing glycemic control, modest weight loss, and blood pressure reduction. Indicated for type 2 diabetes mellitus, with proven cardiorenal benefits.
Dapagliflozin 10mg + Metformin Hydrochloride (Extended Release) 500mg Tablets
Metformin Hydrochloride and Dapagliflozin unites a biguanide with an oral sodium-glucose co-transporter 2 (SGLT2) inhibitor on the WHO Model List of Essential Medicines. Metformin reduces hepatic glucose production and enhances insulin sensitivity, while dapagliflozin acts insulin-independently in the proximal renal tubules to block glucose reabsorption, promoting the urinary excretion of approximately 70-80 grams of glucose per day (equating to 280-320 kcal/day), producing glycemic control, modest weight loss, and blood pressure reduction. Indicated for type 2 diabetes mellitus, with proven cardiorenal benefits.
Dapagliflozin Tablets 5mg
Dapagliflozin (5 mg, 10 mg) is a pioneer selective sodium-glucose co-transporter 2 (SGLT2) inhibitor on the WHO Model List of Essential Medicines. It acts in the S1 segment of the renal proximal tubule, blocking glucose and sodium reabsorption and promoting the urinary excretion of 70 to 80 grams of glucose per day. In addition to glycemic reduction, it induces osmotic diuresis, decreases intraglomerular pressure, reduces cardiac preload and afterload, and confers landmark cardio-renal protection. Indicated for type 2 diabetes mellitus, heart failure with reduced or preserved ejection fraction (HFrEF/HFpEF), and chronic kidney disease (CKD) to slow renal decline.
Dapagliflozin 5mg + Sitagliptin 50mg Tablets
Sitagliptin Phosphate (50 mg, 100 mg) is an orally active, highly selective beta-amino acid-derived dipeptidyl peptidase-4 (DPP-4) inhibitor on the WHO Model List of Essential Medicines. It competitive inhibits DPP-4, preventing the rapid enzymatic degradation of glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), prolonging postprandial active incretin levels. This stimulates glucose-dependent insulin secretion and suppresses postprandial glucagon secretion without causing hypoglycemia or weight gain. Indicated for type 2 diabetes mellitus as monotherapy or combination therapy.